Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Irene Bergna"'
Autor:
Vincenzo De Francesco, Angelo Zullo, Arnaldo Amato, Irene Bergna, Emanuele Bendia, Giorgia Giorgini, Elisabetta Buscarini, Guido Manfredi, Sergio Cadoni, Renato Cannizzaro, Stefano Realdon, Mario Ciuffi, Orazio Ignomirelli, Paola Da Massa Carrara, Giovanni Finucci, Antonietta Di Somma, Chiara Frandina, Mariafrancesca Loria, Francesca Galeazzi, Francesco Ferrara, Carlo Gemme, Noemi Sara Bertetti, Federica Gentili, Antonio Lotito, Bastianello Germanà, Nunzia Russo, Giuseppe Grande, Rita Conigliaro, Federico Cravero, Giovanna Venezia, Riccardo Marmo, Piera Senneca, Angelo Milano, Konstantinos Efthymakis, Fabio Monica, Paolo Montalto, Mario Lombardi, Olivia Morelli, Danilo Castellani, Daniela Nigro, Roberto Festa, Sergio Peralta, Maria Grasso, Antonino Carlo Privitera, Maria Emanuela Di Stefano, Giuseppe Scaccianoce, Mariangela Loiacono, Sergio Segato, Marco Balzarini, Paolo Usai Satta, Mariantonia Lai, Raffaele Manta
Publikováno v:
GE: Portuguese Journal of Gastroenterology, Pp 1-8 (2024)
Background/Aim: Prevalence of gastroduodenal endoscopic and histological lesions may modify over time due to different factors. We assessed both macroscopic and histological lesions currently detected at upper endoscopy performed in routine practice.
Externí odkaz:
https://doaj.org/article/247f7a2243b64789b056418a27f4fa84
Autor:
Francesco Tovoli, Vincenzo Dadduzio, Stefania De Lorenzo, Lorenza Rimassa, Gianluca Masi, Massimo Iavarone, Fabio Marra, Ingrid Garajova, Maria Pia Brizzi, Bruno Daniele, Franco Trevisani, Carlo Messina, Francesco Di Clemente, Sara Pini, Giuseppe Cabibbo, Alessandro Granito, Mario Domenico Rizzato, Vittorina Zagonel, Giovanni Brandi, Tiziana Pressiani, Piera Federico, Caterina Vivaldi, Irene Bergna, Claudia Campani, Fabio Piscaglia
Publikováno v:
Liver Cancer, Vol 10, Iss 4, Pp 370-379 (2021)
Introduction: Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib is also being tested in combination with immune checkpoint inhibitors in the frontli
Externí odkaz:
https://doaj.org/article/35465bb2f20d44ce85e4f6039cf0e079
Autor:
Irene Bergna, Giovanni Brandi, Francesco Tovoli, Gianluca Masi, Francesco Di Clemente, Carlo Messina, Giuseppe Cabibbo, Massimo Iavarone, Fabio Piscaglia, Lorenza Rimassa, Tiziana Pressiani, Vincenzo Dadduzio, Stefania De Lorenzo, Piera Federico, Bruno Daniele, Ingrid Garajová, Franco Trevisani, Caterina Vivaldi, Sara Pini, Maria Pia Brizzi, Mario Domenico Rizzato, Claudia Campani, Alessandro Granito, Fabio Marra, Vittorina Zagonel
Publikováno v:
Liver Cancer
Liver Cancer, Vol 10, Iss 4, Pp 370-379 (2021)
Liver Cancer, Vol 10, Iss 4, Pp 370-379 (2021)
Introduction: Cabozantinib has been approved by the European Medicine Agency (EMA) for hepatocellular carcinoma (HCC) previously treated with sorafenib. Cabozantinib is also being tested in combination with immune checkpoint inhibitors in the frontli
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c30ffb0cfd2b26ba1bebc28e57750e32
http://hdl.handle.net/11568/1107002
http://hdl.handle.net/11568/1107002
Publikováno v:
Liver international : official journal of the International Association for the Study of the Liver. 41(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b82596a1c2411cfc4631a884d263768
https://pubmed.ncbi.nlm.nih.gov/33155346
https://pubmed.ncbi.nlm.nih.gov/33155346